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33 Summary
34 Background: Surveillance of antimicrobial resistance (AMR) in horses is important to aid empirical 
35 treatment decisions and highlight emerging AMR threats. 
36 Objective: To describe the AMR patterns of common groups of bacteria from clinical submissions from 
37 horses in the UK during 2018, and to determine how this varies by sample site and type of submitting 
38 veterinary practice. 
39 Study design: Prospective observational study. 
40 Methods: All data on bacterial culture and subsequent antimicrobial susceptibility testing (AST) collected in 
41 2018 from six large equine diagnostic laboratories were included. Resistance patterns were analysed 
42 including resistance to 1 or 2 antimicrobial classes, multidrug resistance (MDR), extensively drug resistant 
43 (XDR), resistance to highest priority critically important antimicrobials and isolates where there was no 
44 readily available treatment for adult horses in the UK. Submitting practices were classified according to 
45 whether they treated referral cases or not (first opinion). Comparisons between proportions and resistance 
46 for each bacterial group and sample site was performed using Chi squared (or Fisher’s exact test). 
47 Results: A total of 6018 bacterial isolates from 4038 diagnostic submissions were included from respiratory 
48 (n=1555), urogenital (n=1010), skin/hair/wound/abscess (n=753), surgical site infection (SSI) /catheter-
49 related-infection (CRI) /orthopaedic infections (n=347) and unknown/‘other’ submissions (n=373). There 
50 were 2711 Gram-negative isolates and 3307 Gram-positive isolates. Prevalence of MDR for E. coli was 
51 31.7%, Staphylococcus spp. 25.3% and >25% for the majority of bacterial isolates from 
52 SSI/CRI/orthopaedic submissions. For Enterococcus spp. there was no readily available treatment for adult 
53 horses in the UK in 30.2% of positive submissions. MDR was significantly higher from referral hospital than 
54 first opinion submissions for the majority of pathogens (except Actinobacillus spp. and Pasteurella spp. and 
55 β-haemolytic Streptococcus spp.). 
56 Main limitations: Since culture and susceptibility results are not systematic analyses based on harmonised 
57 methods, selection bias could impact the findings. 
58 Conclusions: Ongoing surveillance is essential to understand emerging patterns of resistance. MDR is 
59 high in SSI/CRI/orthopaedic infections, which is important for hospital biosecurity and guiding treatment 
60 decisions. Harmonisation of diagnostic procedures and interpretation of results amongst veterinary 
61 laboratories will improve AMR surveillance and data comparison amongst laboratories. 
62
63 IntroductionA
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
64 Antimicrobial resistance (AMR) is a global problem with implications for both human and equine health [1]. 
65 AMR in horses poses a threat not only to the individual horse but also to the owners and caregivers as well 
66 as to the environment from faecal and urine excretion of antimicrobials and their metabolites [2]. This 
67 problem is more concerning since transmission of multidrug resistant (MDR, isolates with acquired non-
68 susceptibility to at least one antimicrobial in three or more antimicrobial classes) pathogenic strains from 
69 animals to humans has also been reported [3]. There are also few antimicrobials available for use in UK 
70 horses due to a limited number of drugs being authorised for use in this species, cost implications and 
71 safety concerns due to hindgut fermentation. Certain antimicrobial classes, such as macrolides, which are 
72 commonly used in humans and other veterinary species, are rarely used in horses over 12 months of age 
73 (although macrolides are used in foals in the treatment of Rhodococcus pneumonia). Similarly, 
74 lincosamides are never used in horses due to risk of severe and potentially fatal colitis [4,5]. Some 
75 antimicrobials such as doxycycline and enrofloxacin, which are considered safe for use in horses but are 
76 not authorised for equine use in the UK, are frequently prescribed under the cascade for treating equine 
77 infections [6]. Other antimicrobials authorised for use in other veterinary species are rarely used in adult 
78 horses due to cost (e.g. amoxicillin), even though they are considered safe to use in adult horses [6].
79 Surveillance of AMR in clinical isolates is important in order to monitor and detect emerging resistance 
80 patterns, which may be a threat to horse or human health. In addition, surveillance data can be used to 
81 guide policies on antimicrobial use and local geographical empirical therapy. Antimicrobial stewardship and 
82 appropriate antimicrobial prescribing practices are also important to ensure antimicrobials remain effective, 
83 especially with limited treatment options in the horse.  Intrinsic resistance (IR), the innate ability of wild type 
84 bacterial species to resist activity of a particular antimicrobial [7], is particularly high in some bacterial 
85 species that are commonly isolated in horses e.g. Enterococcus spp. and Pseudomonas spp. [8], which 
86 further limits treatment options and may be compounded by acquired resistance also present in such 
87 bacteria. 
88 Previous reports in horses have mostly focused on susceptibility patterns of particular bacteria [9] or from a 
89 particular sample site [10] or age group [11], or used results from a single hospital or laboratory [9]. Recent 
90 publications from France have reported on susceptibility patterns from a variety of bacteria from clinical 
91 submissions from 2012 to 2016 and identified increasing resistance to trimethoprim-sulfamethoxazole in 
92 Streptococcus spp. and E. coli [12]. Another report from France identified a decrease in MDR in E. coli and 
93 Staphylococcus aureus clinical isolates from 2006 to 2016, however prevalence of MDR still remained 
94 above 18% and 22.5% for S. aureus and E. coli, respectively [13]. The Defra AHT BEVA Equine Quarterly 
95 Disease Surveillance Report [14] provides information on the prevalence of bacteria such as Streptococcus 
96 equi subspecies equi (S. equi), methicillin resistant Staphylococcus aureus (MRSA) and several other 
97 bacteria; however, it does not report on antimicrobial susceptibility of these organisms. Whilst there are 
98 several studies reporting on carriage of AMR in bacterial isolates in horses, to the authors’ knowledge, 
99 there is currently a lack of data on antimicrobial susceptibility patterns in bacterial isolates from equine 
100 clinical submissions globally.A
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101 In the UK, a variety of different types of independent diagnostic laboratories operate; these include those 
102 based within large private equine hospitals, university-based laboratories, large commercial veterinary 
103 laboratories that predominantly process small animal submissions with fewer equine submissions, as well 
104 as small in-house laboratories with mainly internal submissions. Currently, there are no standardised 
105 veterinary laboratory methods in the UK, although most laboratories use Clinical and Laboratory Standards 
106 Institute (CLSI) standards for performing antimicrobial susceptibility testing (AST) and for interpretation of 
107 clinical breakpoints [15]. Culture and susceptibility data is crucial for informing treatment decisions and 
108 determining emerging AMR threats. Therefore, the aim of the study was to describe the prevalence of 
109 bacteria most commonly isolated from clinical specimens and patterns of AMR amongst bacterial isolates 
110 from equine clinical samples submitted to diagnostic laboratories in the UK over a twelve-month period in 
111 2018. We hypothesised that there would be increased MDR from submissions from referral practices 
112 compared to first opinion practices, as referral caseloads are more likely to have already been administered 
113 first line antimicrobial treatment, with subsequent referral only following treatment failure.
114
115 Materials and methods
116 Data Collection
117 Bacterial culture and subsequent AST data from bacterial isolates were obtained from clinical submissions 
118 during the calendar year 2018, from six equine diagnostic laboratories across England, including 
119 commercial, practice-based and University-based laboratories. Microorganisms isolated from positive 
120 cultures were identified using commercial biochemical tests including API kits (Biomerieux, France) and 
121 GNID and GPID Sensititre Identification plates (TREK Diagnostic Systems, West Sussex, UK) at four of the 
122 laboratories, while two used the Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry 
123 (MALDI-TOF MS) platform for bacterial species identification (Bruker Daltonics, Germany). AST was 
124 performed using minimum inhibitory concentration (MIC) at two laboratories while the remaining four used 
125 Kirby-Bauer disc diffusion testing. All laboratories used CLSI methods and used CLSI breakpoints where 
126 available for horses. When no breakpoints were available for horses, other veterinary breakpoints were 
127 used, followed by human breakpoints (CLSI or EUCAST) if no other veterinary breakpoints were available 
128 [15]. The individual breakpoints used by each lab for the most common bacteria in this study are listed in 
129 Table S1 and although many breakpoints were identical (e.g. benzyl-penicillin for β-haemolytic 
130 Streptococcus spp., Pasteurella spp. and Actinobacillus spp., oxytetracycline and doxycycline for 
131 Enterobacteriaceae and folate pathway inhibitors for Acinetobacter spp.), some differed between 
132 laboratories (e.g. oxytetracycline and doxycycline for bacteria other than Enterobacteriaceae). No 
133 laboratories used urine specific breakpoints. Breakpoints were displayed to reflect whether MIC or Kirby-
134 Bauer disc diffusion testing was performed. Laboratories also used different antimicrobial susceptibility 
135 panels (Table S2). From all laboratories, a range of information was provided including a unique 
136 submission identification code: first part of the postcode of the submitting veterinary practice address; date A
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137 the results report was produced; the type or anatomical location of the submitted clinical specimen; the 
138 bacterial culture and AST results for each bacterial species isolated from clinical specimens. 
139 Due to laboratories using different antimicrobial panels, antimicrobials were grouped by class. IR was not 
140 included when determining the susceptibility of isolates. Bacteria giving intermediate results i.e. not fully 
141 susceptible were categorised as resistant [8]. Table 1 shows the classification of IR by bacterial species 
142 and was developed by the authors using available relevant recent literature [8,15–18], whilst taking into 
143 account equine pharmacokinetic and pharmacodynamic interactions and available antimicrobials for 
144 horses, including those not authorised for horses but prescribed under the cascade. Antimicrobial 
145 prescriptions under the cascade is a unique UK and Irish process [19] and antimicrobials commonly used 
146 for both authorised and non-authorised use in horses and their Committee for Medicinal Products for 
147 Veterinary Use (CVMP) category is shown in Table S3. In the latest documentation by the CVMP [20], 
148 antimicrobials readily available in the UK for horses include Category A (“Avoid”) - rifampicin; Category B 
149 (“Restrict”) – 3rd and 4th generation cephalosporins (3/4GC) and fluoroquinolones; Category C (”Caution”) – 
150 aminoglycosides; Category D (“Prudence”) – metronidazole, benzylpenicillins, folate pathway inhibitors and 
151 tetracyclines. Royal College of Veterinary Surgeons (RCVS) Veterinary Practice Directory (VPD) and the 
152 National Statistics Postcode Look-up (NSPL) was used to determine if the submitting practice was a 
153 practice that accepted referral cases. Submissions from practices that accepted referral cases and with an 
154 ambulatory branch also were categorised as referral.
155 Data analysis
156 Sample sites were categorised into five different categories as follows: 1. respiratory tract/guttural pouch, 2. 
157 urogenital, 3. skin/hair/wound/abscess, 4. surgical site infection (SSI)/catheter related infection 
158 (CRI)/orthopaedic infections, 5. other or absent. Orthopaedic infections included positive synovial cultures, 
159 septic tendinitis and osteomyelitis submissions and were grouped with SSI and CRI as these infections are 
160 difficult to treat and often require surgery and hospitalisation. Unknown submissions included those where 
161 no site was reported (n=520 isolates from 447 submissions), whilst ‘others’ were those present in less than 
162 100 isolates and included the following sites; faecal (n=25), peritoneal fluid (n=33), liver (n=11), dental 
163 (n=4), gastric (n=7) and rectal (n=5) submissions. 
164 Bacterial species were separated, based on their IR and genetic similarity into the following groups: for 
165 Gram-negative bacteria E. coli; Actinobacillus spp. & Pasteurella spp.;  Citrobacter spp., Enterobacter spp., 
166 Klebsiella spp., Serratia spp., & Pantoea spp.; Pseudomonas spp.;  Acinetobacter spp.; Proteus spp., 
167 Morganella spp., and Providencia spp.; for Gram-positive bacteria β-haemolytic Streptococcus spp.; α-
168 haemolytic Streptococcus spp.; Staphylococcus spp.;  Enterococcus spp.;  Corynebacterium spp. & 
169 Bacillus spp. Although there are CLSI MIC breakpoints for amikacin only for β-haemolytic Streptococcus 
170 spp., EUCAST expert rules considers all Streptococcus spp. IR to all aminoglycosides [16] due to 
171 increasing levels of resistance hence this classification was used for the methods for this project. 
172 Confidence intervals (95% CIs) for the proportions resistant were calculated using the Wilson Score A
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173 intervals [21]. ‘Broadly susceptible isolates’ were those which were susceptible to all classes of 
174 antimicrobials tested (IR excluded) and described in Table 1; ‘Resistant to 1 or 2 classes’ were those 
175 resistant to one or two antimicrobials from different classes; MDR was defined as isolates with acquired 
176 non-susceptibility to at least one antimicrobial in three or more antimicrobial classes. ‘XDR isolates’ were 
177 those which were resistant to all classes of antimicrobials considered [8]. Isolates with ‘no readily available 
178 treatment for adult horses in the UK’ included those that were not susceptible to any of the following 
179 antimicrobials; penicillin (penicillin G), 3rd generation cephalosporins (3GC; ceftiofur), aminoglycosides 
180 (gentamicin/amikacin), tetracyclines (oxytetracycline/doxycycline), folate pathways inhibitors (trimethoprim-
181 sulfamethoxazole), fluoroquinolones (enrofloxacin) or phenicols (chloramphenicol). Polymyxin B, although 
182 tested for using Kirby-Bauer disc diffusion methods by two laboratories was not included due to inaccuracy 
183 of this method; testing using MIC by microbroth dilution is advocated [22]. Additionally, although polymyxin 
184 B may be used in horses as part of treatment of systemic inflammatory response syndrome (SIRS), it is 
185 used at an anti-endotoxic dose rate and not at an antimicrobial dose rate. The recommended dose for 
186 polymyxin B in the treatment of SIRS in horses is 6,000 iu/kg IV every 8 to 12 hours although the dose 
187 range varies between 5,000 -10,000 iu/kg [23–26]. The antimicrobial dose is higher (20,000 iu/kg), although 
188 neurotoxic and nephrotoxic effects have been seen at this dose [27,28] hence should not be used in 
189 horses. The human antimicrobial polymyxin B dose is 30,000 iu/kg/day [29]. Comparisons between 
190 proportions for sample site, referral or first opinion practice and resistance for each bacterial group was 
191 performed using Chi squared (or Fisher’s exact test, [f] when sample size in any category was <5) [21]. A 
192 p-value of <0.05 was considered statistically significant. A bi-variate choropleth map was constructed 
193 displaying geographical variation in the proportion of MDR isolates across all isolates and for those bacteria 
194 that were present in sufficient numbers for analysis. 
195
196 Results
197 AST data were available from 6018 bacterial isolates obtained from 4038 clinical submissions during 2018 
198 and included 1555 respiratory, 1010 urogenital, 753 skin/hair/wound/abscess, 347 SSI/CRI/orthopaedic 
199 infections and 373 unknown or ‘other’ submissions. A single pure bacterial isolate was recovered from 
200 63.6% (2553/4038) of submissions, while the remaining submissions revealed polymicrobial cultures 
201 ranging from 2-7 isolates. Out of the remaining 1485 submissions there were 1093, 319, 66, 3, 1 and 3 
202 submissions with 2, 3, 4, 5, 6 and 7 isolates, respectively. The 6018 bacterial isolates included 2711 Gram-
203 negative isolates and 3307 Gram-positive isolates. Only isolates belonging to the major bacterial groups 
204 identified in Table 1 were included (n=5698) for AMR and MDR calculations, omitting 212 and 108 other 
205 Gram-negative and Gram-positive bacterial isolates, respectively (breakdown shown in Table S4).
206 The submissions came from 208 veterinary practices distributed across the UK (shown in Figure 1). The 
207 most common Gram-positive bacterial isolate was β-haemolytic Streptococcus spp. (45.9%) followed by 
208 Staphylococcus spp. (28.6%; in this group 56.8% were S. aureus, see Table S4 for further information) and A
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209 α-haemolytic Streptococcus spp. (11.0%). In the β-haemolytic Streptococcus spp., the majority were 
210 unspecified species (54.4%) followed by Streptococcus equi subspecies zooepidemicus (S. 
211 zooepidemicus) (34.2%), Streptococcus dysgalactiae subsp. equisimilis (8.4%) and S. equi (3.0%). E. coli 
212 (38.3%) represented the most common Gram-negative isolates followed by Actinobacillus spp. & 
213 Pasteurella spp. (22.8%) and Citrobacter spp., Enterobacter spp., Klebsiella spp., Serratia spp., & Pantoea 
214 spp. (16.9%). The full breakdown of bacterial isolates is shown in Table S4. The most common bacterial 
215 isolates from respiratory submissions included β-haemolytic Streptococcus spp. (31.1%) and Actinobacillus 
216 spp. & Pasteurella spp. (21.6%), while the most common urogenital pathogens included E. coli (31.9%) and 
217 β-haemolytic Streptococcus spp. (29.5%).  The most common bacterial isolates from 
218 skin/hair/wound/abscess submissions included Staphylococcus spp. (32.2%) and β-haemolytic 
219 Streptococcus spp. (20.0%), while SSI/CRI/orthopaedic infections, also most commonly included 
220 Staphylococcus spp. (28.1%) but also E. coli (18.8%) and Enterococcus spp. (12.2%). The breakdown of 
221 AMR in bacterial isolates according to sample site is shown in Table 2. 
222 Antimicrobial resistance
223 The proportion of resistance of bacterial isolates is shown in Table 2 and Table 3. Resistance to 1 or 2 
224 antimicrobial classes was most common in Enterococcus spp. (66.5%), Acinetobacter spp. (63.1%) and β-
225 haemolytic Streptococcus spp. (45.2%). In Gram-negative isolates there was high tetracycline and folate 
226 pathway inhibitor resistance in E. coli (48.0% and 44.3%, respectively) and Citrobacter spp., Enterobacter 
227 spp., Klebsiella spp., Serratia spp., and Pantoea spp. (42.8% and 35.1%, respectively); high folate pathway 
228 inhibitor resistance in Acinetobacter spp. (70.2%) and Proteus spp., Morganella spp., & Providencia spp. 
229 (57.5%); and high macrolide resistance in Actinobacillus spp. & Pasteurella spp. (82.7%). Resistance to 
230 3/4GC in E. coli and Citrobacter spp., Enterobacter spp., Klebsiella spp., Serratia spp. and Pantoea spp. 
231 was 14.0% and 27.6%, respectively. Prevalence of fluoroquinolone resistance was >20% for Pseudomonas 
232 spp., Proteus spp., Morganella spp., and Providencia spp. and >10% for E. coli, Citrobacter spp., 
233 Enterobacter spp., Klebsiella spp., Serratia spp. and Pantoea spp. and Acinetobacter spp. 
234 In Gram-positive isolates there was a very high prevalence of tetracycline resistance in Enterococcus spp. 
235 (49.6%) and >30% for Staphylococcus spp. and β-haemolytic Streptococcus spp. Fluoroquinolone 
236 resistance was also high in Enterococcus spp. (50.7%) but lower in β-haemolytic Streptococcus spp. 
237 (27.9%) and <15% for other relevant Gram-positive isolates. The prevalence of oxacillin or cefoxitin 
238 resistance in Staphylococcus spp. isolates was 15.9%, however only 34.3% of isolates (315 of 916 
239 isolates) were tested against either of these antimicrobials. In S. aureus the prevalence of oxacillin or 
240 cefoxitin resistance was 12.1% (30 of 247 isolates).
241 Multidrug and extensively drug resistant isolates
242 MDR was high in Corynebacterium spp. & Bacillus spp. (50.8%), E. coli (31.7%), Citrobacter spp., 
243 Enterobacter spp., Klebsiella spp., Serratia spp., & Pantoea spp. (25.3%) and Staphylococcus spp. 
244 (25.3%). Isolates with no readily available treatment for adult horses in the UK were highest in A
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245 Enterococcus spp. (30.2%) followed by Acinetobacter spp. (9.2%), while in all other bacterial isolates this 
246 category accounted for less than 6.4% of isolates. The most broadly susceptible isolates included α-
247 haemolytic Streptococcus spp. (92.1%), Pseudomonas spp. (60.1%), Actinobacillus spp. & Pasteurella spp. 
248 (51.7%). Proportion of broadly susceptible, resistant to 1 or 2 classes, MDR and XDR is shown in Table 3. 
249 Resistance by sampling site
250 The most frequent source of bacterial isolates included respiratory (n=2334), urogenital (n=1286), 
251 skin/hair/wound/abscess (n=1230), SSI/CRI and orthopaedic infections (n=549). The proportion of bacterial 
252 isolates with resistance and MDR by species and sample site is shown in Table 2. Proportions of resistance 
253 varied significantly by sample sites with SSI/CRI and orthopaedic infections having high prevalence of MDR 
254 and resistance to most antimicrobials tested for many in many of the bacterial species including E. coli, 
255 Citrobacter spp., Enterobacter spp., Klebsiella spp., Serratia spp., & Pantoea and Acinetobacter spp.  and 
256 Staphylococcus spp. MDR was also prevalent in samples from unknown and other sites in Actinobacillus 
257 spp. & Pasteurella spp., Proteus spp., Morganella spp., & Providencia spp., and Staphylococcus spp. Of 
258 concern, resistance to 3/4GC was >20% in E. coli isolates and > 35% in Acinetobacter spp. from 
259 SSI/CRI/orthopaedic infections and unknown/other.  Resistance to 3/4GC was ≥ 40% in Citrobacter spp., 
260 Enterobacter spp., Klebsiella spp., Serratia spp., & Pantoea spp. from respiratory, SSI/CRI/orthopaedic 
261 infections and unknown/other. Fluoroquinolone resistance was >45% in SSIs for Citrobacter spp., 
262 Enterobacter spp., Klebsiella spp., Serratia spp., & Pantoea spp. and Pseudomonas spp. and >50% for β-
263 haemolytic Streptococcus spp. from SSI/CRI/orthopaedic infections and unknown/other and >75% in 
264 Enterococcus spp. from SSI/CRI/orthopaedic infections and unknown/other.
265 Submitting practice demographics
266 From the 4038 original submissions, there were 3926 where the submitting practice details included a UK 
267 veterinary practice postcode, of which 2008 were referral submissions and 1918 first opinion submissions. 
268 Submissions were excluded (n=112) either due to submitting practice details not being recorded (n=6), or 
269 submissions were from outside of the UK (n=106). There were significantly more respiratory and SSI/CRI 
270 and orthopaedic submissions from practices with referral caseloads (p<0.001), while urogenital, 
271 skin/hair/wound/abscess, and unknown/other submissions were higher from first opinion practices 
272 (p<0.001) (Table 4). From the 5861 isolates which belonged to the major bacterial groups with AST results 
273 presented in Table 2, postcode data was available for 5564 isolates.  This included 2422 Gram-negative 
274 and 3142 Gram-positive isolates with 2820 isolates from referral and 2744 isolates from first opinion 
275 practices. The proportions of MDR in bacterial isolates were significantly different in referral hospitals 
276 compared with first opinion practices (Table 5). MDR was significantly higher in submissions from referral 
277 hospitals in E. coli (p<0.001), Citrobacter spp., Enterobacter spp., Klebsiella spp., Serratia spp., & Pantoea 
278 spp. (p<0.001), Acinetobacter spp. (p<0.001), Staphylococcus spp. (p<0.001), and Enterococcus 
279 spp.(p=0.01). MDR was significantly higher in submissions from first opinion practices in Actinobacillus spp. 
280 & Pasteurella spp. (p<0.001), and β-haemolytic Streptococcus spp. (p<0.001). The majority of S. equi were A
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281 from first opinion submissions (77.3%), while only 18.1% were from referral practices. The majority of S. 
282 zooepidemicus were also from first opinion submissions (64.9%) while 33.7% were from referral practices. 
283 In unspecified β-haemolytic Streptococcus, which made up 54.4% of all β-haemolytic Streptococcus spp. 
284 72.2% were from referral practices. Where data were available regarding postcode (n=5861), a bi-variate 
285 choropleth map displaying the proportion of MDR isolates (and standard error) for each UK constituent 
286 postcode area identified variations in MDR across the UK (shown in Figure 2) across all isolates and for 
287 those bacteria which were present in large enough numbers for analysis (E. coli, β-haemolytic 
288 Streptococcus spp. and Staphylococcus spp.) Though descriptive, this revealed some postcode areas with 
289 relatively higher resistance prevalence and low standard errors.
290
291 Discussion
292 This is the largest study investigating bacterial isolates and their resistance patterns from equine clinical 
293 submissions to multiple laboratories in the UK and provides important information on AMR in common 
294 equine pathogens. The current study identified potential geographical differences in MDR for the most 
295 common bacterial isolates as well as significantly different prevalence of resistance in bacterial isolates 
296 from different sample sites and from referral practices compared to first opinion practices. These variables 
297 are unlikely to be independent; for example, there was increased MDR in SSI/CRI and orthopaedic isolates, 
298 however the majority of these were from referral practices (80.3%) where horses may be more likely to 
299 have received previous antimicrobials, having undergone surgery, have co-morbidities such as systemic 
300 inflammatory response syndrome (SIRS) after colic surgery, or be/have been hospitalised (although the 
301 exact proportion hospitalised is unknown). In isolates from SSI/CRI and orthopaedic infections in the major 
302 categories (listed in Table 1) from referral practices, 37.7% (160/424) were MDR. Previous studies have 
303 reported increased AMR and MDR in clinical isolates from hospitalised compared with non-hospitalised 
304 horses [9]. Similar to our study, previous equine studies have also reported lower prevalence of AMR in 
305 bacteria from respiratory and urogenital submission compared to wounds [30]. Human [31] and companion 
306 animal [32] studies have also identified high MDR in hospital-acquired infections due to a variety of factors 
307 such as previous antimicrobials, co-morbidities, duration of hospitalisation and severity of disease. Gram-
308 negative MDR bacteria have been associated with increased mortality in horses with synovial sepsis 
309 (orthopaedic infection) [33]. However, depending on the severity and site of the infection, MDR bacteria 
310 particularly from SSI do not always require systemic antimicrobials as many are superficial infections, which 
311 are often self-limiting. The current human guidelines for SSIs recommend local treatment consisting of 
312 topical antimicrobials in conjunction with debridement and specialist wound dressings [34], as well as 
313 regular bandage changes and close monitoring the progress of the infection. 
314 Knowledge of these MDR bacteria is important in order to implement targeted biosecurity measures such 
315 as increasing hand hygiene when handling surgical patients, high level cleaning of stables between 
316 patients and sampling the stable environment after cleaning and before admitting the next patient in the A
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317 same stable in order to prevent spread of MDR bacteria in the hospital. Ideally patients with MRSA or 
318 ESBL-producing bacteria should be placed in isolation to prevent spread to other horses in the hospital. By 
319 monitoring bacteria in SSI/CRI and orthopaedic infections, hospitals are also better able to identify 
320 breaches in biosecurity if multiple patients develop infections with the same bacteria and AST phenotype. 
321 Surveillance data is also important from a public health aspect to monitor emerging zoonotic bacteria in 
322 companion animals and horses such as toxigenic Corynebacterium ulcerans [35], Clostridium difficile, 
323 Leptospira spp. or Staphylococcus spp. [36]. In addition to submissions with missing postcodes, 8.6% 
324 (520/6018) of isolates had the sample site information missing, which is similar to human [37,38] and other 
325 veterinary studies [39] where information was commonly missing from diagnostic submission forms. 
326 Isolates from unknown sample sites often also had high prevalence of MDR, however this is of limited value 
327 without knowing the source of the samples. We elected to include “unknown” site for completeness of 
328 reporting, and to highlight the importance of encouraging submitting veterinarians to provide more complete 
329 information on diagnostic submissions for improved laboratory reporting and surveillance. Knowledge of the 
330 sample site is also valuable information for the microbiology laboratory to allow adherence to appropriate 
331 culture protocols according to the sample site and also for the clinical microbiologist  when interpreting the 
332 results and deciding whether the presence of certain bacterial isolates is likely clinically significant or due to 
333 contamination [40]. Unless present as a pure growth from a normally sterile site (such as urine obtained via 
334 cystocentesis), it is difficult to distinguish between simple bacterial presence and true infection [41]. Many 
335 bacterial isolates in equine infections are opportunistic pathogens that may colonise body sites together 
336 with other commensal bacteria [42] and when the conditions are optimal, can cause infections. For 
337 example, MDR Acinetobacter baumannii has been reported in vascular catheters in horses, but only in 
338 42.9% of cases was there evidence of local infection [43]. Immunocompromised patients in particular, are 
339 at risk of infections caused by diverse bacteria, including opportunistic pathogens [44] and anatomical 
340 differences between different sexes and age groups may also predispose to infection [45]. Furthermore, 
341 administration of antimicrobials exerts selective pressure on commensal bacterial populations within a host, 
342 which can select for opportunistic pathogens, for example S. aureus on mucosal surfaces of carriers 
343 following cephalosporin exposure will undergo collateral selective pressure, conferring advantage to 
344 resistant subpopulations, including MRSA [46]. 
345 This study identified increased MDR in submissions from referral practices compared to first opinion 
346 practices in common opportunistic pathogens, such as E. coli, Citrobacter spp., Enterobacter spp., 
347 Klebsiella spp., Serratia spp., and Pantoea spp., Acinetobacter spp., Staphylococcus spp. and 
348 Enterococcus spp. Interestingly, there was increased MDR in submissions from first opinion practices for 
349 Actinobacillus spp. and Pasteurella spp. and β-haemolytic Streptococcus spp. These are common 
350 respiratory and mucosal pathogens [47], but surprisingly there were significantly more respiratory 
351 submissions from practices with referral caseloads, which is different to a previous study where 64% of  β-
352 haemolytic Streptococcus submissions were from non-hospitalised horses [9]. In the current study, the 
353 majority of S. equi (77.3%) and S. zooepidemicus (64.9%) were from first opinion submission while the 
354 majority of unspecified β-haemolytic Streptococcus spp. (72.2%) were from referral submissions hence it is A
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355 difficult to comment further on the pathogenicity of these isolates. However, as submissions from practices 
356 with both referral and first opinion caseloads were categorised as referral, it was not possible to distinguish 
357 further between submissions and it is possible there was some misclassification. Some of these referral 
358 respiratory submissions are likely to originate from some large equine practices that have both hospital and 
359 ambulatory branches and may undertake more poor performance/subclinical respiratory disease screening 
360 in sport and racehorses rather than sampling horses with overt clinical disease which may have biased 
361 these results. In these horses, S. zooepidemicus, for example, is viewed as performance limiting, which 
362 may well be associated with tracheal mucus and inflammatory airway disease and is likely to be treated 
363 with antimicrobials [48]. As it was not possible to distinguish between upper and lower respiratory tract 
364 submissions, it is not possible to explore this further. 
365 It is important to highlight that despite there being higher prevalence of MDR in β-haemolytic Streptococcus 
366 spp. in first opinion submissions than referral submissions, overall MDR in β-haemolytic Streptococcus spp. 
367 was only 8.3% and importantly 97.5% of isolates were susceptible to penicillin, which is the current first line 
368 treatment for equine respiratory infections listed in the BEVA Protect ME toolkit [49]. As described in the 
369 methods in this study, all Streptococcus spp. were considered intrinsically resistant to aminoglycosides 
370 according to EUCAST Expert Rules [16]. Increased doses may overcome this low-level of intrinsic 
371 resistance although this may not be practical or safe in equine practice. Interestingly in recent reports from 
372 clinical isolates from horses in France gentamicin resistance was low (1.2%) in all Streptococcus spp. 
373 (75.1% of all streptococci in that study were S. zooepidemicus), although that study used a high 
374 concentration of gentamicin (500µg) for AST. Similarly, in respiratory submissions in horses from New 
375 Zealand, gentamicin resistance was low in all Streptococcus spp. (7.4%) despite that study using a lower 
376 standard concentration of gentamicin (10µg) for AST [10] than the French study. In contrast, a previous UK 
377 study identified high prevalence of resistance to gentamicin (ranging from 50-74%) in β-haemolytic 
378 Streptococcus spp. with increasing resistance in S equi, Streptococcus equisimilis and unidentified β-
379 haemolytic Streptococcus spp. from 2004-2012 [9] using a standard concentration of gentamicin (10µg). 
380 However, these results need to be interpreted with some caution, as older CLSI interpretation guidelines 
381 were used [50–52]. Similarly, in β-haemolytic Streptococcus spp. from respiratory submissions in UK 
382 horses, gentamicin and streptomycin resistance were 100%, which adds further evidence that all 
383 Streptococcus spp. should be considered resistant to aminoglycosides [53]. Other differences include high 
384 enrofloxacin (68.4%) and tetracycline (60.1%) resistance in French Streptococcus spp. [12], while in the 
385 current study fluoroquinolone (27.9%) and tetracycline (33.8%) resistance was much lower in β-haemolytic 
386 Streptococcus spp. Similar to the French study, there was a high prevalence of resistance to tetracycline in 
387 β-haemolytic Streptococcus spp. (66.7-100%) in a recent study of clinical respiratory submissions from 
388 horses in the UK, although MDR was low (<1%) [53]. The higher prevalence of tetracycline resistance in 
389 the study by Fonseca et al. is in contrast to the current study despite both studies undertaken in UK horses. 
390 This may reflect a temporal change in susceptibility patterns as the previously published study was 
391 conducted between 2002-2012 while the current study only included isolates sampled in 2018. Other 
392 differences may represent international variation which may be driven by different equine populations, A
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393 antimicrobial use or differences in emerging resistance in Streptococcus spp. and highlights the necessity 
394 of local surveillance for informing current antimicrobial guidelines [54]. These results could also suggest 
395 possible differences in methodology and interpretation of results between these studies, which highlights 
396 the need for harmonisation of susceptibility testing amongst laboratories at country or European level for 
397 enhanced AMR surveillance. 
398 There are several bacterial isolates with high levels of IR leaving only two treatment options available in 
399 adult horses, particularly for Enterococcus spp., Pseudomonas spp., and α-haemolytic Streptococcus spp., 
400 which are only considered susceptible to tetracyclines and fluoroquinolones; aminoglycosides and 
401 fluoroquinolones; 3GC and fluoroquinolones, respectively. These bacteria are considered susceptible to 
402 few other antimicrobials (e.g. ampicillin/macrolides/extended spectrum penicillins/β-lactamase 
403 inhibitors/4GC), which are not safe or available for use in horses in the UK. Thus, using a classification of 
404 MDR of resistance to 3 or more classes may not be suitable for organisms such as Pseudomonas spp. and 
405 Enterococcus spp., which have multiple inherent resistance mechanisms and very few antimicrobials to 
406 which they are expected to be susceptible to. Therefore, for these bacterial isolates MDR is often artificially 
407 low (<4% in this study) despite there often being no readily available treatment options in adult horses in 
408 the UK (30.2% for Enterococcus spp.). It is important to recognise that bacterial isolates with high IR should 
409 not be overlooked due to their low MDR as they pose a therapeutic challenge when involved in infection 
410 [55]. These bacteria, as well as posing a risk for the individual horse, are also of zoonotic concern as they 
411 have also been reported in humans. A genotypically identical strain of Pseudomonas spp. from a water 
412 source has been reported as a cause of an outbreak of equine endometritis in Australia [56], from a variety 
413 of equine samples in Ireland [57], from companion animals [58] and from human cystic fibrosis patients 
414 [59]. Enterococcus spp. are common pathogens in hospital-acquired infections in humans [60], equine 
415 synovial infections [61] and companion animals [62] and have been associated with increased mortality in 
416 foals [63]. However, they are often present in human and animal gut flora [64], on skin [64] and urogenital 
417 mucosa [65] and therefore are often present in clinical specimens as contaminants [66,67]. It is important 
418 that their clinical significance is thoroughly evaluated, and susceptibility testing is issued only when their 
419 clinical significance is established. Future studies should investigate the relevance of Enterococcus spp. by 
420 including cytological evidence of association with infection. Alpha-haemolytic Streptococcus spp., in 
421 particular S. pneumoniae, are also troublesome to treat and are a common cause of human sepsis [68] and 
422 have been reported in bacteraemia and pneumonia in a neonatal foals [69] and companion animals [70]. 
423 These bacteria form an exceptional clinical challenge in human and veterinary medicine, as the isolates are 
424 frequently MDR and have susceptibility patterns that are difficult to predict [60,71,72].
425 Our study identified higher MDR compared to a recent study of clinical isolates in France, where the 
426 highest MDR was 22.5% (S. aureus). MDR in Staphylococcus spp. in our study was slightly higher (25.3%) 
427 with high MDR in other common opportunistic pathogens such as E. coli (31.7%) and Citrobacter spp., 
428 Enterobacter spp., Klebsiella spp., Serratia spp., & Pantoea spp. (25.3%). This is similar to other studies in 
429 the UK where MDR in clinical E. coli from horses was 39.9% [9]. MRSA and EBSL-producing A
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430 Enterobacteriaceae are common bacterial isolates in nosocomial infections and of much clinical interest. It 
431 was not possible to report the exact prevalence of these organisms in this study due to no confirmatory 
432 genotyping or phenotypic testing being performed in the majority of laboratories. The prevalence of oxacillin 
433 or cefoxitin resistant S. aureus isolates was 6.1% which is lower than the prevalence of cefoxitin resistant 
434 S. aureus from horses in France (23%). The highest prevalence of oxacillin or cefoxitin resistant S. aureus 
435 in the current study were from SSI/CRI/orthopaedic (21.6%, 16/74) and urogenital (6.6%, 3/44) and 
436 skin/hair/wound/abscess (2.3%, 5/ 214). This included isolates from one laboratory that used PCR-assay to 
437 confirm presence of mecA gene [73] and this gene was identified in 26.3% (5/19) of oxacillin or cefoxitin 
438 resistant S. aureus in this laboratory. Although MRSA screening was based on oxacillin or cefoxitin testing 
439 which could result in an overestimation of the real proportion of MRSA, our results indicate that oxacillin or 
440 cefoxitin resistant S. aureus are less prevalent in UK than French submissions. Most laboratories did not 
441 perform phenotypic testing to detect ESBL-producers in 3/4GC resistant Gram-negative isolates hence the 
442 prevalence of ESBL-producers cannot be reported.  However resistance to 3/4GC in the current study was 
443 14.0% of E. coli and 27.6% in Citrobacter spp., Enterobacter spp., Klebsiella spp., Serratia spp., & Pantoea 
444 spp., which is higher than in E. coli (7.6%) and Klebsiella spp. (5.2%) in clinical isolates from France [12], 
445 but similar to a previous UK study where 3GC resistance in E. coli was 14.2% [9]. There was a lower 
446 prevalence of ceftiofur resistance in E. coli from respiratory submissions in horses in the UK (0-2.9%) than 
447 the current study, while in Pseudomonas spp. 3GC resistance was higher (over 64.6%) compared with the 
448 current study (11.1%) [53]. 
449 The current study has some inherent limitations. The results were generated from different laboratories 
450 using slightly different antimicrobial panels and different technical equipment and staff. Since interpretative 
451 criteria of disc diffusion data are set, so there is optimal correlation with MIC from microbroth dilution, for 
452 most bacterial species from both human and veterinary samples, one method of susceptibility testing is not 
453 considered superior to the other [74–78] for the majority of antimicrobials against bacterial species such as 
454 Salmonella spp., Enterobacteriaceae, A. baumannii [77,79–81]. For some bacterial species there are 
455 discrepancies between the methods in particular for methicillin-resistant Staphylococcus pseudintermedius 
456 (MRSP) and for some antimicrobials when testing against Pseudomonas spp. and Corynebacterium spp. 
457 [78,82,83]. For polymyxin B and colistin disc diffusion methods are not recommended as these do not 
458 diffuse well in agar [84] and microbroth dilutions are also recommended for S. pneumoniae (α-haemolytic 
459 Streptococcus spp.) to penicillins and some cephalosporins due to better accuracy [85,86]. Larger and 
460 more modern laboratories are commonly using automated microbroth dilution methods due to its versatility 
461 and ability to determine the MIC likely to achieve effective antimicrobial plasma concentration. This means 
462 that if the MIC indicates that an isolate is susceptible but at the higher end of the range, near the 
463 epidemiological cut off value (ECOFF), it may require a higher dose to achieve therapeutic concentrations 
464 [87]. Although there are also inaccuracies in MIC, such that the accepted MIC ranges of quality control 
465 strains, often span over two to three dilutions and even four dilutions in some cases [88]. Smaller 
466 laboratories often use Kirby-Bauer disc diffusion methods due to lower costs and no requirement for 
467 extensive equipment. Furthermore, another limitation was that a pooled approach to reporting was utilised A
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468 by combining some bacterial species based on their similarities in intrinsic resistance patterns. This is 
469 similar to human studies [8] and was done in order to avoid having several smaller groups making 
470 conclusions and  presentation of results difficult, but the authors acknowledged that this does somewhat 
471 limit the application of these pooled results.
472 The current study reports on the presence of different bacterial isolates from clinical submissions and all 
473 isolates with reported susceptibility were included in this study.  However, some bacteria may be 
474 contaminants such as Bacillus spp. and Enterococcus spp., and Pseudomonas spp. in some submissions. 
475 Although in the majority of submissions only a single bacterial isolate was reported, it is difficult to establish 
476 the main pathogenic organism in polymicrobial cultures [41], which is another limitation of the current study 
477 and a general challenge of diagnostic microbiology. However, in this study we identified less polymicrobial 
478 cultures (36.4%) than previously reported in equine respiratory submissions where 58.2-76.4% of cultures 
479 yielded polymicrobial growth [53]. Performing AST on  multiple isolates from the same specimen without 
480 consideration of clinical relevance, does not promote prudent antimicrobial prescribing practices [89]. 
481 Bacterial isolates with intermediate susceptibility were considered resistant, as treatment with an 
482 antimicrobial with intermediate susceptibility would likely not be recommended in most situations in a 
483 clinical infection and is also consistent with reporting in other EU and UK surveillance projects [90,91]. In 
484 circumstances where there are no other treatment options, antimicrobial therapy may be guided by MIC to 
485 safely determine the antimicrobial dose for an antimicrobial agent with intermediate susceptibility. As 
486 certain antimicrobials are excreted in urine, such as penicillin and folate pathway inhibitors, higher 
487 concentration can be achieved in urine. There are a small number of breakpoints specific to urinary tract 
488 infections (UTI) for this reason (e.g. for amoxicillin in Enterobacteriaceae in dogs), but it is not relevant to 
489 include these breakpoints as they were not utilised by any of the laboratories in this study. Classifying 
490 intermediate susceptibility as resistant, is likely to have overestimated resistance outcomes, including MDR. 
491 Furthermore, intermediate susceptibility may incorrectly reflect the outcome in topical use in cases involving 
492 the eye/skin/wounds where resistance was relatively high in this study. Care is also warranted over 
493 overestimation of susceptibility for treatment of infections confined in the central nervous system, or 
494 systemic use of antimicrobials for treatment of infections in the eye, where some antimicrobials may 
495 penetrate poorly. Although these were not common sites reported in this study. It was also not possible to 
496 assess the way samples were collected and for example obtaining a respiratory sample via a nasal swab 
497 has higher potential for contamination compared with obtaining a trans-tracheal wash (TTW) or 
498 bronchoalveolar lavage (BAL) sample. 
499 Another limitation is the inherent selection bias associated with clinical submissions, as infections, which 
500 are not responding to treatment, are more likely to be submitted and similarly, infections which are 
501 responding to treatment, are often not sampled, particularly in non-hospitalised horses. This is a limitation 
502 common to clinical diagnostic microbiology data, which is unavoidable. However these sources of data are 
503 a valuable part of AMR surveillance in humans [90,92] and other veterinary animal species [91,93] and can 
504 help to identify new and emerging patterns of resistance, particularly because treatment failure is a frequent A
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505 reason for submission of samples. Furthermore, there are likely to be differences in prudency in sampling 
506 between different practices and veterinary surgeons. The use of different AST methods and different 
507 clinical breakpoints is considered a major limitation but is a problem common to other multi-laboratory 
508 studies [93,94] and in well-established reports of resistance on bacteria from human invasive infections 
509 [90]. This limitation was unavoidable and also complicates comparison of resistance amongst current and 
510 future surveillance studies. Harmonisation of methods and interpretative criteria in veterinary medicine 
511 should be a priority and would allow future comparisons over time in resistance frequencies. There are 
512 national and international systems for monitoring and reporting AMR in food-producing animals, such as 
513 the National Antimicrobial Resistance Monitoring System in the USA and the harmonised monitoring of 
514 AMR conducted in the EU. However, systematic surveillance systems for AMR in veterinary clinical 
515 samples are frequently lacking, and surveillance of this kind is not currently carried out for AMR in horses. 
516 Even systems such as the RESAPATH network in France [95], which is a national passive surveillance 
517 system that includes equine samples, have the inherent biases associated with voluntary submission of 
518 results by laboratories and selection of cases for sampling by practising vets [12]. The European 
519 Antimicrobial Resistance Surveillance Network (EARS-Net) for monitoring AMR in organisms associated 
520 with human diseases is based on routine clinical antimicrobial susceptibility data that is reported to the 
521 European Centre for Disease Prevention and Control by EU countries and the UK  [90]. The data originate 
522 from national AMR surveillance initiatives and laboratory networks. Furthermore, the veterinary medicines 
523 directorate (VMD) collates data from  laboratories on AMR in bacteria in samples from animals in the 
524 annual Veterinary Antimicrobial Resistance and Sales Surveillance (VARSS) report [91]. This is managed 
525 through two programmes: EU Harmonised Monitoring, and a clinical surveillance programme, which relies 
526 on voluntary submission of samples by farmers and veterinary surgeons although this has limited data from 
527 equine and companion animals. Current efforts include developing a system for diagnostic surveillance of 
528 AMR in veterinary medicine, European Antimicrobial Resistance Veterinary Surveillance Network (EARS-
529 VET) [96], which eventually may include equine data. The role of the veterinary committee on AST, 
530 VetCAST [97] and ENOVAT (European Network for Optimization of Veterinary Antimicrobial Treatment) 
531 [98] may be crucial in this harmonisation process. However, veterinary laboratories must adopt the same 
532 laboratory standards in order to achieve this [99]. There are many barriers to implementation of harmonised 
533 methods including cost and availability of equipment, skills and training of the laboratory staff, and the time-
534 consuming nature of updating the latest breakpoints while running a commercial service. As there is no 
535 governing body which veterinary laboratories have to subscribe to that regulates or audits methods and 
536 results, laboratories are able to use their own in-house methods. Despite these limitations, the results from 
537 this study provide relevant and updated information on the current AMR situation in clinical bacterial 
538 isolates from horses in the UK. 
539 Apart from establishing if practices were referral or first opinion, it was not possible to determine further 
540 practice characteristics such as case load. Descriptive spatial analysis suggested there may be 
541 geographical differences in levels of resistance prevalence, as has been observed in humans [100,101]. 
542 However, in the current study, data were based on the submitting practice postcode, rather than horse or A
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543 owner location, and it is therefore not accurate to compare geographical differences. Furthermore, the 
544 submissions were from a limited number of diagnostic laboratories, hence the results from this study are 
545 not representative of all infections encountered in horses in the UK. Further research and surveillance are 
546 needed to enable practitioners to utilise local resistance trends to guide prescribing. The study did identify 
547 that current guidelines regarding first line antimicrobials are relevant, such as recommendation for 
548 trimethoprim-sulphadiazine for first line treatment for most urogenital conditions [49] [where the most 
549 common bacterial isolates were E. coli (31.9%) and β- haemolytic Streptococcus spp. (29.5%)], unless the 
550 infection is due to Proteus spp., Morganella spp., and Providencia spp., (83.3% resistance) or 
551 Acinetobacter spp. (62.5% resistance), or any of the bacteria which are IR to such as Pseudomonas spp., 
552 α-haemolytic Streptococcus spp. or Enterococcus spp. Although these bacterial isolates combined 
553 accounted for only 16.1% (198/1227) of bacterial isolates from urogenital submissions in the current study, 
554 it does highlight the need for culture and susceptibility testing in infections, which are not responding to first 
555 line treatment. 
556
557 Conclusion 
558 This study provides important information about patterns of AMR in major equine pathogens in the UK. Our 
559 results are useful for veterinarians to guide their initial empirical treatment. Our results also emphasise the 
560 importance of antimicrobial stewardship and judicious use of antimicrobials especially in horses undergoing 
561 surgery as SSI/CRI and orthopaedic infections had increased levels of MDR. It also highlights the need for 
562 concerted efforts for harmonisation and standardisation of culture and susceptibility methods at least at 
563 national level to support AMR surveillance. Furthermore, resistance patterns were different in referral and 
564 first opinion submission, which is vital information for risk assessment and implementation of biosecurity 
565 measures. This study only provides information on equine isolates submitted during 2018 and ongoing 
566 surveillance is recommended to determine differences in seasonality and to detect emerging trends in 
567 AMR. 
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886 Figure legends:
887 Fig 1: Map showing the spread of postcodes of the 208 veterinary practices that contributed to 3926 
888 equine diagnostic submission in this study during 2018 in the UK.
889 Fig 2: Quintile bivariate postcode map displaying the proportion of multidrug resistant (MDR) equine 
890 bacterial isolates that were submitted by veterinary practice sites in the UK. Only bacterial isolates 
891 present in sufficient numbers for analysis were included showing (A) overall, (B) -haemolytic 
892 Streptococcus spp., (C) E.coli, (D) Staphylococcus spp. Proportions are displayed against standard error to 
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893 provide a measure in relative confidence in findings depending on data volume provided within each 
894 postcode area.
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896 Table 1: List of antimicrobial classes and agent used to define multidrug resistance (MDR) for common 
897 bacterial isolates in horses (modified from resources in literature such as Magiorakos et al. 2012, EUCAST 
898 3.1 and CLSI VET08 ED4:2018) and Giguère, S., Prescott, J.F. and Dowling, P.M. (Eds.). (2013). 
899 Antimicrobial Therapy in Veterinary Medicine. John Wiley & Sons.) GC- Generation Cephalosporin. 
900 Lincosamides such as Clindamycin and Lincomycin were not included where relevant (Pasteurella spp.& 
901 Actinobacillus spp; Staphylococcus spp; α and β-haemolytic Streptococcus spp.; Corynebacterium spp.& 
902 Bacillus spp.) as they were only rarely tested for (approx. 1% of isolates) and there is no readily available 
903 treatment option in adult horses in the UK. Intrinsic resistance (IR) to antimicrobial agents for each 
904 genus/species are listed at the bottom of each group.
Bacterial genus 
or species 
Antimicrobial Class Antimicrobial Agent
Amino-penicillins Ampicillin
Amoxicillin
Beta-lactamase inhibitor combinations Amoxicillin-clavulanic acid
Ticarcillin-clavulanic
Piperacillin-tazobactam
3rd and 4th GCs Cefotaxime
Ceftazidime
Cefpodoxime
Ceftiofur 
Cefquinome
Aminoglycosides Gentamicin
Amikacin
Neomycin
Framycetin
Tobramycin
Tetracyclines Oxytetracycline
Doxycycline
Folate pathway inhibitors Trimethoprim sulphadiazine
Trimethoprim-sulfamethoxazole
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Phenicols Chloramphenicol
Escherichia coli
Intrinsic resistance: benzyl-penicillins and macrolides
Benzyl-penicillins Penicillin GPenicillins
Amino-penicillins Ampicillin
Amoxicillin
Beta-lactamase inhibitor combinations Amoxicillin-clavulanic acid
Ticarcillin-clavulanic acid
Piperacillin-tazobactam
Gram-
negative
3rd and 4th GCs Cefotaxime
Ceftazidime
Cefpodoxime
Ceftiofur 
CefquinomeA
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Bacterial genus 
or species 
Antimicrobial Class Antimicrobial Agent
Aminoglycosides Gentamicin
Amikacin
Neomycin
Framycetin
Tobramycin
Tetracyclines Oxytetracycline
Doxycycline
Folate pathway inhibitors Trimethoprim sulphadiazine
Trimethoprim-sulfamethoxazole
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Macrolides Erythromycin
Clarithromycin
Azithromycin
Phenicols Chloramphenicol
Pasteurella spp. 
&, Actinobacillus 
spp.
Intrinsic resistance: Pasteurella spp. &, Actinobacillus spp. are considered IR to 1 & 2nd 
GC, and Actinobacillus spp. are considered IR to benzyl-penicillins.
Extended-spectrum β-lactamase inhibitor 
combinations
Ticarcillin-clavulanic
Piperacillin-tazobactam
3rd and 4th GCs Cefotaxime
Ceftazidime
Cefpodoxime
Ceftiofur 
Cefquinome
Aminoglycosides Gentamicin
Amikacin
Neomycin
Framycetin
Tobramycin
Tetracyclines Oxytetracycline 
Doxycycline
Folate pathway inhibitors Trimethoprim sulphadiazine
Trimethoprim-sulfamethoxazole
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Phenicols Chloramphenicol
Citrobacter spp., 
Enterobacter 
spp., Klebsiella 
spp., Serratia 
spp., & Pantoea 
spp.
Intrinsic resistance: benzyl and amino penicillins, 1 & 2nd GCs and macrolides
Extended-spectrum β-lactamase inhibitor 
combinations
Ticarcillin-clavulanic acid
Piperacillin-tazobactam
3rd and 4th GCs Ϯ Ceftazidime 
Cefquinome
Pseudomonas 
spp.
Aminoglycosides Gentamicin
Amikacin
Neomycin
Framycetin
TobramycinA
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Bacterial genus 
or species 
Antimicrobial Class Antimicrobial Agent
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Intrinsic resistance: benzyl and amino penicillins, 1&2nd GCs, tetracyclines, folate pathway 
inhibitors, phenicols and macrolides. . Ϯ Ceftazidime/Cefquinome only
Extended-spectrum β-lactamase inhibitor 
combinations
Ticarcillin-clavulanic acid
Piperacillin-tazobactam
3rd and 4th GCs‡ Cefotaxime
Ceftazidime
Cefquinome
Aminoglycosides Gentamicin
Amikacin
Neomycin
Framycetin
Tobramycin
Folate pathway inhibitors Trimethoprim sulphadiazine
Trimethoprim-sulfamethoxazole
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Acinetobacter
 spp.
Intrinsic resistance: benzyl and amino penicillins, 1&2nd GCs, tetracyclines, phenicols and 
macrolides. ‡Cefotaxime/Ceftazidime/Cefquinome only
Extended-spectrum β-lactamase inhibitor 
combinations
Ticarcillin-clavulanic acid
Piperacillin-tazobactam
3rd and 4th GCs Cefotaxime
Ceftazidime
Cefpodoxime
Ceftiofur 
Cefquinome
Aminoglycosides Gentamicin₫
Amikacin
Neomycin
Framycetin
Tobramycin
Folate pathway inhibitors Trimethoprim sulphadiazine
Trimethoprim-sulfamethoxazole
Phenicols Chloramphenicol
Proteus spp., 
Morganella spp., 
& Providencia 
spp.,
Intrinsic resistance: benzyl and amino penicillins, 1&2nd GCs, tetracyclines and macrolides. 
₫ -Gentamicin excluded for Providencia spp.
Anti-staphylococcal β-lactam OxacillinФ
CefoxitinФ
Aminoglycosides Gentamicin
Amikacin
Neomycin
Framycetin
Tobramycin
Staphylococcus 
spp. (coagulase 
positive and 
negative) Tetracyclines Oxytetracycline
DoxycyclineA
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Bacterial genus 
or species 
Antimicrobial Class Antimicrobial Agent
Folate pathway inhibitors Trimethoprim sulphadiazine
Trimethoprim-sulfamethoxazole
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Macrolides Erythromycin
Clarithromycin
Azithromycin
Phenicols Chloramphenicol
Fusidanes Fusidic acid
Ansamycins Rifampicin
Intrinsic resistance: benzyl and amino penicillins and all cephalosporins.  Ф Diagnostic 
purpose (no treatment option horses)
Benzyl-penicillins Penicillin GPenicillins
Amino-penicillins Ampicillin
Amoxicillin
Beta-lactamase inhibitor combinations Amoxicillin-clavulanic acid
Ticarcillin-clavulanic acid
Piperacillin-tazobactam
 3rd and 4th GC Cefotaxime
Ceftazidime
Cefpodoxime
Ceftiofur 
Cefquinome
Tetracycline Doxycycline
Oxytetracycline
Folate pathway inhibitors Trimethoprim sulphadiazine
Trimethoprim-sulfamethoxazole
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Macrolides Erythromycin
Clarithromycin
Azithromycin
Phenicols Chloramphenicol
Beta-haemolytic 
Streptococcus 
spp. 
Intrinsic resistance: aminoglycosides
3rd and 4th GCs Ceftiofur
Cefquinome
Macrolides (only in combination) Erythromycin
Clarithromycin
Azithromycin
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Gram-
positive
Alpha-
haemolytic 
Streptococcus 
spp. 
Intrinsic resistance: benzyl and amino penicillins, beta-lactamase inhibitor combinations, 
1&2nd GCs, aminoglycosides, tetracyclines, folate pathway inhibitors, macrolides and 
phenicols. A
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Bacterial genus 
or species 
Antimicrobial Class Antimicrobial Agent
Amino/Ureido- Penicillins Ampicillin
Amoxicillin
Ticarcillin
Tetracyclines Doxycycline
Oxytetracycline
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Enterococcus 
spp.  
Intrinsic resistance: benzyl penicillin, beta-lactamase inhibitor combinations, all 
cephalosporins, aminoglycosides, folate pathway inhibitors, macrolides and phenicols. 
Benzyl-penicillins Penicillin GPenicillin
Amino-penicillins Ampicillin
Amoxicillin
Beta-lactamase inhibitor combinations Amoxicillin-clavulanic acid
Ticarcillin-clavulanic acid
Piperacillin-tazobactam
3rd and 4th GCs Cefotaxime
Ceftazidime
Cefpodoxime
Ceftiofur 
Cefquinome
Aminoglycosides Gentamicin
Amikacin
Neomycin
Framycetin
Tobramycin
Tetracyclines Oxytetracycline
Doxycycline
Folate pathway inhibitors Trimethoprim sulphadiazine
Trimethoprim-sulfamethoxazole
Fluoroquinolones Enrofloxacin
Ciprofloxacin 
Marbofloxacin
Macrolides Erythromycin
Clarithromycin
Azithromycin
Phenicols Chloramphenicol
Corynebacteriu
m spp. & 
Bacillus spp.
Intrinsic resistance: none
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Table 2: Proportion of resistance (in %) of 5698 bacteria isolated from clinical infections in horses classified by sample site. P value is provided for comparisons 
between proportions using Chi squared (or Fisher’s exact test (f) when sample size in any category was <5). GC-Generation Cephalosporin, *Penicillin and 
Aminopenicillin combined for Pasteurella spp.  Ϯ- Ceftazidime/Cefquinome only, ‡ Cefotaxime/Ceftazidime/Cefquinome only, ₫ -Gentamicin excluded for 
Providencia spp.  Bacterial isolates where there was <100 in a genus were not included (n=320) from the original 6018. Unknown included those submissions 
where no site was reported (n=520) while ‘others’ were those present in low numbers (n=99) and included sample sites such as faecal, peritoneal fluid, liver, 
dental, gastric and rectal submissions. Full breakdown of bacterial isolates is shown in Table S4.
Proportion of resistant isolates by sample site, % (total tested)
Pathogen 
(n)
Antimicrobial
Total 
number 
of 
isolates
tested
Proportion of 
resistance (% and 
95%CI)
Respiratory 
(2187)
Urogenital 
(1227)
Skin/Wound 
(1163)
SSI/CRI/Orth
opaedic (526)
Unknown & 
Other (595)
P value
Gram-negative bacteria 2499 45.4 (992) 52.2 (641) 34.3 (400) 41.1 (216) 42.0 (250)
Total 958 8.4 (183) 31.9 (391) 13.1 (152) 18.8 (99) 22.4 (133)
Aminopenicillins 627 35.4 (31.8-39.2) 39.0 (141) 27.3 (300) 44.9 (91) 64.6 (48) 29.8 (47) <0.001
β-lactamase inhibitor 
combinations
402 8.7 (6.3-11.9) 7.0 (158) 12.2 (41) 9.6 (104) 12.2 (49) 6.0 (50) 0.5 (f)
3/4th GCs 955 14.0 (12.0-16.4) 11.5 (183) 9.0 (390) 14.6 (151) 23.5 (98) 24.8 (133) <0.001
Aminoglycosides 955 23.4 (20.8-26.1) 18.0 (183) 18.0 (389) 25.0 (152) 43.9 (98) 29.3 (133) <0.001
Tetracyclines 954 48.0 (44.9-51.2) 42.1 (183) 37.1 (388) 55.3 (152) 60.2 (98) 70.7 (133) <0.001
Escherichia 
coli (958)
Folate pathway 945 44.3 (41.2-47.5) 37.0 (181) 38.1 (381) 53.3 (152) 60.2 (98) 50.4 (133) <0.001
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Proportion of resistant isolates by sample site, % (total tested)
Pathogen 
(n)
Antimicrobial
Total 
number 
of 
isolates
tested
Proportion of 
resistance (% and 
95%CI)
Respiratory 
(2187)
Urogenital 
(1227)
Skin/Wound 
(1163)
SSI/CRI/Orth
opaedic (526)
Unknown & 
Other (595)
P value
inhibitors
Fluoroquinolones 955 10.7 (8.9-12.8) 9.3 (183) 5.9 (389) 17.1 (152) 21.4 (98) 11.3 (133) <0.001
Phenicols 204 26.5 (20.9-32.9) 28.0 (25) 11.8 (34) 24.4 (41) 28.0 (25) 32.9 (79) <0.001
MDR 958 31.7 (28.9-34.8) 30.6 (183) 21.5 (391) 37.5 (152) 50.5 (99) 42.9 (133) <0.001
Total 571 21.6 (472) 1.3 (16) 3.7 (43) 3.6 (19) 3.5 (21)
Aminopenicillins* 493 16.0 (13.1-19.5) 15.3 (425) 36.4 (11) 17.1 (35) 10.0 (10) 27.3 (11) <0.001 (f)
β-lactamase inhibitor 
combinations
462 0.6 (0.2-1.9) 0.2 (408) 25.0 (4) 3.3 (30) 0.0 (9) 0.0 (11) <0.001 (f)
3/4th GCs 570 2.5 (1.5-4.1) 2.5 (471) 6.3 (16) 2.3 (43) 0.0 (19) 0.0 (21) 0.02 (f)
Aminoglycosides 571 32.2 (28.5-36.2) 29.4 (472) 37.5 (16) 34.9 (43) 63.2 (19) 57.1 (21) <0.001
Tetracyclines 571 5.8 (4.1-8.0) 4.9 (472) 6.3(16) 7.0 (43) 15.8 (19) 14.3 (21) 0.03 (f)
Folate pathway 
inhibitors
571 15.9 (13.2-19.2) 15.3 (472) 18.8 (16) 14.0 (43) 26.3 (19) 23.8 (21) 0.1 (f)
Fluoroquinolones 571 3.7 (2.4-5.6) 3.2 (472) 0.0 (11) 4.7 (43) 15.8 (19) 4.8 (21) <0.001 (f)
Macrolides 104 82.7 (74.3-88.8) 85.3 (68) 88.9 (9) 75.0 (8) 60.0 (10) 88.9 (9) <0.001
Phenicols 93 5.4 (2.3-12.0) 6.7 (60) 0.0 (5) 0.0 (13) 0.0 (6) 11.1 (9) <0.001 (f)
Actinobacill
us spp. & 
Pasteurella 
spp. (571) 
MDR 571 9.3 (7.2-11.9) 7.8 (472) 18.8 (16) 9.3 (43) 15.8 (19) 28.6 (21) <0.001 (f)
Total 423 7.2 (158) 9.9 (121) 5.5 (64) 8.7 (46) 5.9 (34)Citrobacter 
spp., 
Enterobacte
Extended spectrum 
penicillins /β-
16 0 (0.0-19.4) 0.0 (6) 0 (4) 0 (2) 0 (5) 0 (4) >0.9 (f)
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Proportion of resistant isolates by sample site, % (total tested)
Pathogen 
(n)
Antimicrobial
Total 
number 
of 
isolates
tested
Proportion of 
resistance (% and 
95%CI)
Respiratory 
(2187)
Urogenital 
(1227)
Skin/Wound 
(1163)
SSI/CRI/Orth
opaedic (526)
Unknown & 
Other (595)
P value
lactamase inhibitors
3/4th GCs 420 27.6 (23.6-32.1) 13.9 (158) 26.4 (121) 27.0 (63) 56.8 (44) 58.8 (34) <0.001
Aminoglycosides 423 25.3 (21.4-29.7) 15.8 (158) 18.2 (121) 21.9 (64) 73.9 (46) 35.3 (34) <0.001
Tetracyclines 423 42.8 (38.2-47.6) 28.5 (158) 38.8 (121) 50.0 (64) 78.3 (46) 61.8 (34) <0.001
Folate pathway 
inhibitors
416 35.1 (30.7-39.8) 21.7 (157) 33.3 (117) 38.1 (63) 75.6 (45) 44.1 (34) <0.001
Fluoroquinolones 423 12.8 (9.9-16.3) 5.7 (158) 9.9 (121) 9.4 (64) 47.8 (46) 14.7 (34) <0.001
Phenicols 101 23.8 (16.5-32.9) 34.6 (26) 0 (21) 22.7 (22) 28.6 (7) 32.0 (25) <0.001 (f)
r spp., 
Klebsiella 
spp., 
Serratia 
spp., & 
Pantoea 
spp. (423)
MDR 423 25.3 (21.4-29.7) 13.3 (158) 16.5 (121) 25.0 (64) 76.1 (46) 44.1 (34) <0.001
Total 286 7.0 (152) 5.6 (69) 3.3 (38) 2.3 (12) 2.5 (15)
Extended spectrum 
penicillins/β-
lactamase inhibitors
13 7.7 (1.4-33.3) 14.3 (7) 0(0) 0(0) 0 (6) 0(0) <0.001 (f)
3/4th GCsϯ 180 11.1 (7.3-16.5) 12.8 (133) 0 (3) 0 (26) 0 (10) 37.5 (8) <0.001 (f)
Aminoglycosides 286 19.9 (15.7-24.9) 21.7 (152) 23.2 (69) 5.3 (38) 33.3 (12) 13.1 (15) <0.001 (f)
Fluoroquinolones 285 23.5 (19.0-28.8) 17.8 (152) 23.5 (68) 28.9 (38) 41.7 (12) 53.3 (15) <0.001
Pseudomon
as spp. 
(286)
MDR 286 0.7 (0.2-2.5) 1.3 (152) 0 (69) 0 (38) 0 (12) 0 (15) >0.9 (f)
Total 141 1.1 (24) 2.6 (32) 4.4 (51) 3.6 (19) 2.5 (15)Acinetobact
er spp. 
(141)
Extended spectrum 
penicillins/β-
6 0 (0.0-39.0) 0 (1) 0(0) 0 (1) 0 (4) 0 (1) >0.9 (f)
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Proportion of resistant isolates by sample site, % (total tested)
Pathogen 
(n)
Antimicrobial
Total 
number 
of 
isolates
tested
Proportion of 
resistance (% and 
95%CI)
Respiratory 
(2187)
Urogenital 
(1227)
Skin/Wound 
(1163)
SSI/CRI/Orth
opaedic (526)
Unknown & 
Other (595)
P value
lactamase inhibitors
3/4th GCs‡ 118 23.7 (17.0-32.2) 20.8 (24) 13.3 (15) 18.4 (49) 41.2 (17) 38.5 (13) <0.001 (f)
Aminoglycosides 141 19.2 (13.5-26.4) 8.3 (24) 6.3 (32) 17.6 (51) 57.9 (19) 20.0 (15) <0.001 (f)
Folate pathway 
inhibitors
141 70.2 (62.2-77.1) 62.5 (24) 71.9 (32) 68.6 (51) 73.7 (19) 80.0 (15) 0.09
Fluoroquinolones 139 15.8 (10.7-22.8) 8.3 (24) 9.4 (32) 15.7 (51) 29.4 (17) 26.7 (15) <0.001 (f)
MDR 141 13.5 (8.8-20.1) 12.5 (24) 0.0 (32) 11.8 (51) 36.8 (19) 20.0 (15) <0.001 (f)
Total 120 0.1 (3) 1.0 (12) 4.5 (52) 4.0 (21) 5.4 (32)
Extended spectrum 
penicillins/β-
lactamase inhibitors
7 0 (0-35.4) 0 (2) 0 (3) 0 (2) 0 (0) 0 (0) >0.9 (f)
3/4th GCs 120 19.2 (13.1-27.1) 0 (3) 8.3 (12) 7.7 (52) 19.0 (21) 43.8 (32) <0.001 (f)
Aminoglycosides₫ 120 32.5 (24.8-41.3) 0 (3) 33.3 (4) 23.1 (52) 33.3 (21) 50.0 (32) <0.001 (f)
Folate pathway 
inhibitors
120 57.5 (48.6-66.0) 33.3 (3) 83.3 (12) 42.3 (52) 76.2 (21) 62.5 (32) <0.001 (f)
Fluoroquinolones 120 25.0 (18.1-33.4) 0 (3) 16.7 (12) 23.1 (52) 28.6 (21) 31.3 (32 <0.001 (f)
Phenicols 53 34 (22.7-47.4) 0 (0) 0 (2) 30.8 (13) 45.5 (11) 30.0 (30) <0.001 (f)
Proteus 
spp., 
Morganella 
spp., & 
Providencia 
spp., (120)
MDR 120 26.7 (19.6-35.2) 0 (3) 16.7 (12) 15.4 (52) 33.3 (21) 46.9 (32) <0.001 (f)
Gram-positive bacteria 3199 54.6 (1195) 47.8 (586) 65.6 (763) 58.9 (310) 58.0 (345)
Beta Total 1467 31.3 (685) 29.5 (362) 20.0 (233) 10.3 (54) 22.0 (131)
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Proportion of resistant isolates by sample site, % (total tested)
Pathogen 
(n)
Antimicrobial
Total 
number 
of 
isolates
tested
Proportion of 
resistance (% and 
95%CI)
Respiratory 
(2187)
Urogenital 
(1227)
Skin/Wound 
(1163)
SSI/CRI/Orth
opaedic (526)
Unknown & 
Other (595)
P value
Penicillin 1466 2.5 (1.8-3.4) 3.1 (684) 0.8 (362) 3.0 (233) 1.9 (54) 3.0 (133) 0.9 (f)
β-lactamase inhibitor 
combinations
756 0.7 (0.3-1.5) 0.9 (533) 0 (30) 0.0 (145) 0.0 (26) 0.0 (22) >0.9 (f)
3/4th GCs 1467 1.7 (1.2-2.5) 1.8 (685) 0.8 (362) 2.6 (233) 1.9 (54) 2.3 (133) >0.9 (f)
Tetracycline 1460 33.8 (31.5-36.3) 37.8 (685) 19.4 (355) 33.1 (233) 59.3 (54) 42.9 (133) <0.001
Folate pathway 
inhibitors
1465 15.0 (12.2-16.9) 15.7 (683) 15.8 (362) 10.7 (233) 20.4 (54) 14.3 (133) 0.5
Fluoroquinolones 1467 27.9 (25.7-30.2) 25.0 (685) 11.9 (362) 33.9 (233) 50.0 (54) 66.9 (133) <0.001
Macrolides 599 15.4 (12.7-18.5) 12.8 (258) 20.3 (64) 11.1 (126) 26.7 (30) 19.8 (121) <0.001
Phenicols 393 13.7 (10.7-17.5) 13.0 (146) 14.0 (43) 16.5 (79) 13.3 (15) 12.7 (110) >0.9 (f)
haemolytic 
Streptococc
us spp 
(1467)
MDR 1467 8.3 (7.0-9.8) 7.5 (685) 3.9 (362) 6.4 (233) 18.5 (54) 21.8 (133) <0.001
Total 916 7.1 (155) 8.8 (108) 32.2 (374) 28.1 (148) 22.0 (131)
Oxacillin/Cefoxitin 315 15.9Ф (12.3-20.3) 10.7 (28) 28.6 (14) 8.2 (98) 38.6 (70) 7.6 (105) <0.001 (f)
Aminoglycosides 894 24.9 (22.2-27.9) 11.0 (154) 22.4 (107) 18.4 (370) 51.5 (132) 35.1 (131) <0.001
Tetracyclines 894 35.6 (32.5-38.8) 26.0 (154) 34.6 (107) 27.0 (370) 65.2 (132) 42.0 (131) <0.001
Folate pathway 
inhibitors
894 25.8 (23.1-28.8) 15.6 (154) 22.4 (107) 19.5 (370) 47.0 (132) 37.4 (131) <0.001
Fluoroquinolones 893 13.1 (11.3-15.7) 6.5 (154) 8.3 (108) 8.4 (370) 22.9 (131) 30.0 (130) <0.001
Macrolides 407 34.6 (30.2-39.4) 18.6 (59) 29.0 (31) 25.8 (120) 32.6 (86) 55.9 (111) <0.001
Staphylococ
cus spp.  
(916)
Phenicols 259 6.2 (3.8-9.8) 7.4 (27) 27.3 (11) 5.4 (93) 7.4 (27) 4.0 (101) <0.001 (f)
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Proportion of resistant isolates by sample site, % (total tested)
Pathogen 
(n)
Antimicrobial
Total 
number 
of 
isolates
tested
Proportion of 
resistance (% and 
95%CI)
Respiratory 
(2187)
Urogenital 
(1227)
Skin/Wound 
(1163)
SSI/CRI/Orth
opaedic (526)
Unknown & 
Other (595)
P value
Fusidanes 736 15.6 (13.2-18.4) 17.3 (139) 10.9 (46) 11.9 (337) 12.6 (87) 27.6 (127) <0.001
Ansamycins 
(Rifampicin)
724 6.5 (4.9-8.5) 4.5 (112) 7.0 (43) 4.1 (321) 10.7 (122) 10.3 (126) 0.2 (f)
MDR 916 25.3 (22.6-28.2) 14.2 (155) 17.6 (108) 16.6 (374) 44.6 (148) 48.1 (131) <0.001
Total 353 12.7 (277) 1.8 (22) 2.4 (28) 3.8 (20) 1.0 (6)
3/4th GCs 353 0.85 (0.3-2.5) 0.36 (277) 0.0 (22) 3.6 (28) 5.0 (20) 0.0 (6) <0.001 (f)
Fluoroquinolones 352 7.1 (4.9-10.3) 4.7 (276) 13.6 (22) 0.0 (28) 35.0 (20) 33.3 (6) <0.001 (f)
Macrolides 29 10.3 (3.6-26.4) 12.5 (8) 25.0 (4) 0.0 (1) 7.7 (13) 0.0 (3) <0.001 (f)
Alpha 
haemolytic 
Streptococc
us spp. 
(353)
MDR 353 0 (0.0-1.1) 0.0 (277) 0.0 (22) 0.0 (28) 0.0 (20) 0.0 (6) >0.9 (f)
Total 278 2.7 (58) 5.1 (63) 4.0 (46) 12.2 (64) 7.9 (47)
Aminopenicillins 137 10.2 (6.2-16.4) 2.9 (34) 2.8 (36) 12.0 (25) 27.3 (33) 0.0 (9) <0.001 (f)
Tetracyclines 276 49.6 (43.8-55.5) 22.4 (58) 48.4 (62) 54.3 (46) 77.8 (63) 42.6 (47) <0.001
Fluoroquinolones 276 50.7 (44.9-56.7) 13.8 (58) 41.3 (63) 43.5 (46) 79.0 (62) 78.7 (47) <0.001
  
Enterococc
us spp. 
(278)
MDR 278 0.0 (0.0-1.4) 0.0 (58) 0.0 (63) 0.0 (46) 0.0 (64) 0.0 (47) >0.9 (f)
Total 185 0.9 (20) .2.5 (31) 7.1 (82) 4.6 (24) 4.7 (28)
Penicillins 185 70.3 (63.3-76.4) 60.0 (20) 58.1 (31) 72.0 (82) 70.8 (24) 85.7 (28) <0.001
β-lactamase inhibitor 
combinations
85 27.1 (18.8-37.3) 25.0 (12) 50.0 (6) 30.4 (46) 7.7 (13) 25.0 (8)
<0.001 (f)
Corynebact
erium spp. 
& Bacillus 
spp (185)
3/4th GCs 184 52.2 (45.0-59.3) 55.0 (20) 56.7 (30) 53.7 (82) 33.3 (24) 57.1 (28) <0.001
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Proportion of resistant isolates by sample site, % (total tested)
Pathogen 
(n)
Antimicrobial
Total 
number 
of 
isolates
tested
Proportion of 
resistance (% and 
95%CI)
Respiratory 
(2187)
Urogenital 
(1227)
Skin/Wound 
(1163)
SSI/CRI/Orth
opaedic (526)
Unknown & 
Other (595)
P value
Aminoglycosides 185 17.8 (13.0-24.0) 10.0 (20) 9.7 (31) 17.1 (82) 16.7 (24) 35.7 (28) <0.001 (f)
Tetracyclines 185 21.6 (16.3-28.1) 20.0 (20) 9.7 (31) 17.1 (82) 16.7 (24) 35.7 (28) <0.001 (f)
Folate pathway 
inhibitors
185 41.6 (34.8-48.8) 35.0 (20) 41.9 (31) 45.1 (82) 45.8 (24) 32.1 (28) 0.1
Fluoroquinolones 185 12.4 (8.4-18.0) 5.0 (20) 9.7 (31) 7.3 (82) 25.0 (24) 25.0 (28) <0.001 (f)
Macrolides 76 60.5 (49.3-70.8) 75.0 (4) 70.0 (10) 50.0 (32) 60.0 (10) 70.0 (20) <0.001 (f)
Phenicols 89 36.0 (26.8-46.3) 12.5 (8) 22.2 (9) 40.5 (42) 40.0 (10) 40.0 (20) <0.001 (f)
MDR 185 50.8 (43.7-57.9) 45.0 (20) 45.2 (31) 51.2 (82) 41.7 (24) 67.9 (28) <0.001
Ф = For S. aureus prevalence of oxacillin/cefoxitin resistance was 12.1% (30 of 247 isolates tested).
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Table 3: Proportions (in % with 95% CI) of antimicrobial resistance (AMR) in 5698 bacterial isolates from 
clinical infections from horses in the UK from 2018. Broadly susceptible isolates were susceptible to all 
antimicrobials tested. Multidrug resistant (MDR) isolates were those with acquired non-susceptibility to at 
least one antimicrobial in three or more different antimicrobial classes. Extensively drug resistant (XDR) 
isolates were those, which were resistant to all classes of antimicrobials tested. ‘No readily available 
treatment for adult horses in the UK’ included those isolates, which were resistant to commonly used 
(authorised or non-authorised) antimicrobials available for adult horses in the UK. All calculations are based 
on antimicrobials considered in Table 1 and excludes intrinsic resistance.
Bacteria (total
number of
isolates)
Susceptibility patterns
of isolates
Number of 
isolates
Proportion (%
[ 95% CI])
Gram-negative bacteria
Broadly susceptible 342 35.7 (32.7-38.8)
Resistant to 1 or 2 classes 312 32.6 (29.7-35.6)
MDR 304 31.7 (28.9-34.8) 
XDR 23 2.4 (1.6-3.6)
Escherichia coli (958)
No readily available treatment for adult horses 
in the UK
31 3.2 (2.3-4.6)
Broadly susceptible 295 51.7 (47.6-55.7)
Resistant to 1 or 2 classes 223 39.1 (35.1-43.1)
MDR 53 9.3 (7.2-11.9)
XDR 0 0.0 (0.0-0.6)
Actinobacillus spp. & 
Pasteurella spp. (571) 
No readily available treatment for adult horses 
in the UK
0 0.0 (0.0-0.6)
Broadly susceptible 174 41.1 (36.6-45.9)
Resistant to 1 or 2 classes 142 33.6 (29.3-38.2)
MDR 107 25.3 (21.4-29.7)
XDR 6 1.4 (0.7-3.1)
Citrobacter spp., 
Enterobacter spp., Klebsiella 
spp., Serratia spp., & 
Pantoea spp. (423) No readily available treatment for adult horses 
in the UK
26 6.1 (4.2-8.9)
Broadly susceptible 172 60.1 (54.4-65.6)
Resistant to 1 or 2 classes 112 39.2 (33.7-44.9)
MDR 2 0.7 (0.2-2.5)
XDR 0 0.0 (0.0-1.3)
Pseudomonas spp. (286)
No readily available treatment for adult horses 
in the UK
18 6.3 (4.0-9.7)
Broadly susceptible 33 23.4 (17.2-31.0)
Resistant to 1 or 2 classes 89 63.1 (54.9-70.6)
MDR 19 13.5 (8.8-20.1)
Acinetobacter spp. (141)
XDR 6 4.3 (2.0-9.0)A
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Bacteria (total
number of
isolates)
Susceptibility patterns
of isolates
Number of 
isolates
Proportion (%
[ 95% CI])
No readily available treatment for adult horses 
in the UK
13 9.2 (5.5-15.1)
Broadly susceptible 36 30.0 (22.5-38.7)
Resistant to 1 or 2 classes 52 43.3 (34.8-52.3)
MDR 32 26.7 (19.6-35.2)
XDR 3 2.5 (0.9-7.1)
Proteus spp., Morganella 
spp., & Providencia spp., 
(120)
No readily available treatment for adult horses 
in the UK
3 2.5 (0.9-7.1)
Gram-positive bacteria
Broadly susceptible 683 46.6 (44.0-49.1)
Resistant to 1 or 2 classes 663 45.2 (42.7-47.8)
MDR 121 8.3 (7.0-9.8)
XDR 1 0.1 (0.0-0.4)
β-haemolytic Streptococcus 
spp. (1467)
No readily available treatment for adult horses 
in the UK
1 0.1 (0.0-0.4)
Broadly susceptible 427 46.6 (43.4-49.9)
Resistant to 1 or 2 classes 257 28.1 (25.3-31.1)
MDR 232 25.3 (22.6-28.2)
XDR 2 0.2 (0.0-0.8)
Staphylococcus spp.  (916)
No readily available treatment for adult horses 
in the UK
4 0.4 (0.2-1.1)
Broadly susceptible 325 92.1 (88.8-94.5)
Resistant to 1 or 2 classes 28 7.9 (5.5-11.2)
MDR / XDR (*all classes) 0 0.0 (0.0-1.1)
α-haemolytic Streptococcus 
spp. (353)
No readily available treatment for adult horses 
in the UK
1 0.3 (0.0-1.6)
Broadly susceptible 84 30.2 (25.1-35.9)
Resistant to 1 or 2 classes 185 66.5 (60.8-71.8)
MDR / XDR (*all classes) 9 3.2 (1.7-6.0)
Enterococcus spp. (278)
No readily available treatment for adult horses 
in the UK
84 30.2 (25.1-35.9)
Broadly susceptible 26 14.1 (9.8-19.8)
Resistant to 1 or 2 classes 65 35.1 (28.6-42.3)
MDR 94 50.8 (43.7-57.9)
XDR 0 0.0 (0.0-2.0)
Bacillus spp. & 
Corynebacterium spp. (185)
No readily available treatment for adult horses 
in the UK
1 0.5 (0.1-3.0)
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*For α-haemolytic Streptococcus spp. and Enterococcus spp. only three classes on antimicrobials were 
considered hence multidrug resistance is the same as resistance to all classes of antimicrobials tested 
(XDR).
Table 4: Proportion of clinical submissions (n=3926) from different sample sites (in % with 95% CI) from 
clinical infections in horses at referral and first opinion equine practices in the UK in 2018.  P-value is 
provided for comparisons between the proportions of submissions from different practices using Chi 
squared. Clinical submissions without information regarding referral status of submitting practice including 
submissions from abroad were excluded from analysis (n=112). SSI-surgical site infection, CRI-catheter 
related infection.
Referral hospital (n=2008) First opinion practice (n=1918)
Sample Site (n)
Total number of 
submissions
Proportion of isolates 
(% and 95%CI)
Total number of 
submissions
Proportion of 
isolates (% and 
95%CI)
P value
Respiratory tract 
(1505)
885 58.8 (56.3-61.3) 620 41.2 (38.7-43.7) <0.001
Urogenital (990) 406 41.0 (38.0-44.1) 584 59.0 (55.9-62.0) <0.001
Skin/Hair/Wound/Abs
cess (723)
293 40.5 (37.0-44.2) 430 59.5 (55.9-63.0) <0.001
SSI/CRI/Orthopaedic 
Infection (342)
283 82.8 (78.4-86.4) 59 17.3 (13.6-21.6) <0.001
Unknown and other 
(366)
141 38.5 (33.7-43.6) 225 61.5 (56.4-66.3) <0.001
Table 5: Proportion of multidrug resistance (MDR) (in % with 95% CI) in bacteria isolated from clinical 
infections in horses at referral and first opinion equine practices in the UK in 2018 based on 5564 isolates 
with UK postcode data in the major bacterial genera included in this study.  P-value is provided for A
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comparisons between proportions using Chi squared (or Fisher’s exact test (f) when sample size in any 
category was <5). 
Referral hospital (n=2820) First opinion practice (n=2744)
Pathogen (n)
Total number of 
isolates
Proportion of MDR 
(% and 95%CI)
Total number of 
isolates
Proportion of MDR (% 
and 95%CI)
P value
Gram-negative bacteria (n=2422)
Escherichia coli (926) 387 36.7 (32.0-41.6) 539 27.1 (23.5-31.0) <0.001
Actinobacillus spp. & Pasteurella spp. 
(569) 
425 6.4 (4.4-9.1) 144 18.1 (12.6-25.1) <0.001
Citrobacter spp., Enterobacter spp., 
Klebsiella spp., Serratia spp., & 
Pantoea spp. (406)
142 35.2 (27.8-43.4) 264 20.8 (16.4-26.2) <0.001
Pseudomonas spp. (267)* 121 0 (0-3.1) 146 1.4 (0.4-4.9) 0.5 (f)
Acinetobacter spp. (135) 44 27.3 (16.4-41.9) 91 6.6 (3.1-13.7) <0.001
Proteus spp., Morganella spp., & 
Providencia spp., (119)
58 34.5 (23.6-47.3) 61 19.7 (11.6-31.3) 0.1
Gram-positive bacteria (n=3142)
Beta haemolytic Streptococcus spp. 
(1455)
789 5.1 (3.7-6.8) 666 11.7 (9.5-14.4) <0.001
Staphylococcus spp.  (888) 405 34.8 (30.3-39.6) 483 18.4 (15.2-22.1) <0.001
Alpha haemolytic Streptococcus spp. 
(351)*
273 0.0 (0.0-1.4) 78 0.0 (0.0-4.7) >0.9 (f)
Enterococcus spp. (271)* 127 6.3 (3.2-11.9) 144 0.7 (0.1-3.8) 0.01 (f)
Bacillus spp. & Corynebacterium spp. 
(177)
49 44.9 (31.9-58.7) 128 50.8 (42.2-59.3) 0.6
*There are several bacterial isolates with high levels of IR leaving limited treatment options available in 
adult horses (for example Enterococcus spp., Pseudomonas spp., and α-haemolytic Streptococcus spp. 
Thus, using a classification of MDR of resistance to 3 or more classes results often results in artificially low 
MDR estimates despite there being limited treatment options for adult horses hence MDR calculations in 
bacterial isolates with high IR should be interpreted in light of IR. 
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